These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20501465)

  • 1. Effects of cinacalcet on vascular calcification in haemodialysis patients.
    Almirall J; Gallardo X; Castañé E
    Nephrol Dial Transplant; 2010 Aug; 25(8):2800. PubMed ID: 20501465
    [No Abstract]   [Full Text] [Related]  

  • 2. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.
    Floege J; Raggi P; Block GA; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Chertow GM;
    Nephrol Dial Transplant; 2010 Jun; 25(6):1916-23. PubMed ID: 20110249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P; Chertow GM; Torres PU; Csiky B; Naso A; Nossuli K; Moustafa M; Goodman WG; Lopez N; Downey G; Dehmel B; Floege J;
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in coronary artery calcification score due to cinacalcet hydrochloride administration.
    Tsuruta Y; Ohbayashi T; Fujii M; Myochin H; Mizutani R; Narita M; Maeda K
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S34-7. PubMed ID: 19032525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
    Iseki K
    Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
    Owda AK; Alam MG; Kumar J
    N Engl J Med; 2004 Jul; 351(2):188-9; author reply 188-9. PubMed ID: 15247361
    [No Abstract]   [Full Text] [Related]  

  • 7. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
    Yokoyama K
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
    [No Abstract]   [Full Text] [Related]  

  • 8. Cinacalcet, fetuin-A and interleukin-6.
    Marino A; Giotta N
    Nephrol Dial Transplant; 2008 Apr; 23(4):1460-1; author reply 1461-2. PubMed ID: 18065786
    [No Abstract]   [Full Text] [Related]  

  • 9. Cinacalcet: benefit and cost.
    Cohen E
    Nephrol Dial Transplant; 2008 Apr; 23(4):1460; author reply 1460. PubMed ID: 18065795
    [No Abstract]   [Full Text] [Related]  

  • 10. Cinacalcet cost and utility in dialysis patients.
    Cohen E; Uribarri J
    Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
    [No Abstract]   [Full Text] [Related]  

  • 11. Regression of parathyroid gland swelling by treatment with cinacalcet.
    Terawaki H; Nakano H; Takeguchi F; Hasegawa T; Nakayama M; Okazaki M; Hosoya T
    Nephrol Dial Transplant; 2009 Feb; 24(2):690-1; author reply 691-2. PubMed ID: 18987257
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cinacalcet therapy and cardiovascular risk in hemodialysis patients].
    Zelaźnicka M; Kocełak P; Olszanecka Glinianowicz M; Chudek J
    Postepy Hig Med Dosw (Online); 2012 Oct; 66():722-9. PubMed ID: 23175326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)].
    Nagano N; Kawata T; Wada M
    Nihon Yakurigaku Zasshi; 2008 Nov; 132(5):301-8. PubMed ID: 19008642
    [No Abstract]   [Full Text] [Related]  

  • 14. Fooling the parathyroid gland--will there be health benefits?
    Curhan G
    N Engl J Med; 2004 Apr; 350(15):1565-7. PubMed ID: 15071132
    [No Abstract]   [Full Text] [Related]  

  • 15. Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD.
    Olgaard K; Lewin E; Silver J
    Nephrol Dial Transplant; 2011 Apr; 26(4):1117-9. PubMed ID: 21427074
    [No Abstract]   [Full Text] [Related]  

  • 16. Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient.
    Yamada S; Tsuruya K; Kitazono T
    Ther Apher Dial; 2013 Jun; 17(3):348-9. PubMed ID: 23735152
    [No Abstract]   [Full Text] [Related]  

  • 17. Regression of vascular calcification in a patient treated with cinacalcet: a case report.
    Salgueira M; Martínez AI; Milán JA
    Nefrologia; 2011; 31(5):602-6. PubMed ID: 21959728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trials in kidney disease--time to EVOLVE.
    Perkovic V; Neal B
    N Engl J Med; 2012 Dec; 367(26):2541-2. PubMed ID: 23121375
    [No Abstract]   [Full Text] [Related]  

  • 19. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism.
    Jean G; Chazot C; Charra B
    Nephrol Dial Transplant; 2007 Jul; 22(7):2102-3. PubMed ID: 17395648
    [No Abstract]   [Full Text] [Related]  

  • 20. Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis?
    Cannata-Andía JB; Fernández-Martín JL
    Nat Rev Nephrol; 2009 Jun; 5(6):307-8. PubMed ID: 19474823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.